

1 **Summary (150 Words)**

2 In 2022 the World Health Organization declared a Public Health Emergency for an outbreak of mpox,  
3 the zoonotic Orthopoxvirus (OPV) affecting at least 103 non-endemic locations world-wide. Serologic  
4 detection of mpox infection is problematic, however, due to considerable antigenic and serologic cross-  
5 reactivity among OPVs and smallpox-vaccinated individuals. In this report, we developed a high-  
6 throughput multiplex microsphere immunoassay (MIA) using a combination of mpox-specific peptides  
7 and cross-reactive OPV proteins that results in the specific serologic detection of mpox infection with  
8 93% sensitivity and 98% specificity. The New York State Non-Vaccinia Orthopoxvirus Microsphere  
9 Immunoassay is an important diagnostic tool to detect subclinical mpox infection and understand the  
10 extent of mpox spread in the community through retrospective analysis.

11 **Development of a Novel Serological Assay for the Detection of Mpox Infection in Vaccinated**  
12 **Populations**

13 Jennifer L. Yates<sup>1,2</sup>, Danielle T. Hunt<sup>1</sup>, Karen E. Kulas<sup>1</sup>, Karen Chave<sup>1</sup>, Linda Styer<sup>1,2</sup>, Sandhya T.  
14 Chakravarthi<sup>1</sup>, Gianna Y. Cai<sup>11,14</sup>, Maria C. Bermúdez-González<sup>8,11</sup>, Giulio Kleiner<sup>8,11</sup>, Deena Altman<sup>9</sup>,  
15 Komal Srivastava<sup>8,11</sup>, the PVI study group<sup>8,11</sup>, Viviana Simon<sup>8,9,10,11,12</sup>, Dennis Feihel<sup>6,7</sup>, Joseph  
16 McGowan<sup>6,7</sup>, Wayne Hogrefe<sup>5</sup>, Philip Noone<sup>5</sup>, Christina Egan<sup>1,2</sup>, Mark K. Slifka<sup>3,4</sup>, and William T. Lee<sup>1,2</sup>  
17

18 <sup>1</sup> Division of Infectious Diseases, Wadsworth Center, New York State Department of Health, Albany,  
19 NY, USA; <sup>2</sup> Biomedical Sciences, The School of Public Health, The University at Albany, Albany, NY,  
20 USA; <sup>3</sup> Oregon National Primate Research Center, Oregon Health and Science University, Beaverton,  
21 Oregon, USA; <sup>4</sup> Najit Technologies, Inc., Beaverton, OR, USA; <sup>5</sup> Aalto Bio Reagents, Dublin, Ireland;  
22 <sup>6</sup> Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, USA; <sup>7</sup> Department of Medicine North  
23 Shore University Hospital, Manhasset, NY, USA; <sup>8</sup> Department of Microbiology, Icahn School of  
24 Medicine at Mount Sinai, NY, USA; <sup>9</sup> Division of Infectious Diseases, Department of Medicine, Icahn  
25 School of Medicine at Mount Sinai, New York; <sup>10</sup> Department of Pathology, Molecular and Cell Based  
26 Medicine, Icahn School of Medicine at Mount Sinai, NY; <sup>11</sup> Center for Vaccine Research and Pandemic  
27 Preparedness, Icahn School of Medicine at Mount Sinai, NY, USA; <sup>12</sup> The Global Health and Emerging  
28 Pathogens Institute, Icahn School of Medicine at Mount Sinai, NY, USA  
29

30 **Correspondence:** [jennifer.yates@health.ny.gov](mailto:jennifer.yates@health.ny.gov)  
31

32 PVI study group (in alphabetical order): Angela A. Amoako, Dalles Andre, Harm van Bakel, Christian  
33 Cognini, Charles R. Gleason, Ana Gonzalez-Reiche, Morgan van Kesteren, Al Lugo, Neko Lyttle, Jacob  
34 D. Mauldin, Brian C. Monahan, Jessica R. Nardulli, Annika Oostenink, Alberto Paniz-Monodolfi, Jose  
35 Polanco, Juan David Ramírez, Aria Rooker, and Emilia Mia Sordillo.

## 36 Introduction

37 Mpox (formerly known as monkeypox), is a zoonotic orthopoxvirus (OPV) that has historically  
38 been endemic and largely isolated to western and central Sub-Saharan Africa <sup>1, 2</sup>. Other species of  
39 OPVs include cowpox (CPXV), vaccinia (VAC; smallpox vaccine), and variola virus (VAR; smallpox)  
40 which all share a high degree of genetic homology. Mpox can be transmitted through close contact with  
41 an infected person or animal, bodily fluids, respiratory secretions, or consumption of contaminated  
42 meat. Symptoms of infection can be severe and may include lymphadenopathy, fever, headache,  
43 fatigue, muscle aches, flu-like symptoms, and a characteristic rash, and death<sup>3, 4</sup>. In 2003 a non-  
44 endemic mpox outbreak occurred in the United States due to the importation of infected animals. In  
45 total, 71 cases of mpox were detected over 5 months. The outbreak was contained through the  
46 implementation of multiple public-health efforts including restrictions placed on the movement of exotic  
47 animals<sup>5</sup>. In 2022 the world faced a multi-country outbreak of non-endemic mpox, prompting the World  
48 Health Organization to announce a Public Health Emergency of International Concern. To date, over  
49 85,000 cases with 97 deaths have been reported globally with over 30,000 of those cases and 32  
50 deaths occurring in the United States. In contrast to the 2003 outbreak human-to-human transmission  
51 has been the primary mode of viral spread in 2022. The size and geographic distribution of the current  
52 mpox outbreak has highlighted the need for specific tools to diagnose, treat, and monitor immunity to  
53 OPVs.

54 OPVs are large dsDNA viruses that encode up to 200 highly conserved viral proteins resulting in  
55 extensive antigenic and serologic cross-reactivity between members of the OPV genus<sup>6</sup>. The protection  
56 afforded by vaccination with VAC against fatal smallpox infection is based, and dependent on the  
57 antigenic cross-reactivity between VAC and VAR. In the United States, childhood vaccination with VAC  
58 was customary until 1972, and VAC vaccination was reinstated for the US military forces in 2002  
59 resulting in a significant number of US residents with VAC-reactive antibodies<sup>7, 8</sup>. More recently,  
60 JYNNEOS vaccine (Modified Vaccinia Ankara, Bavarian Nordic) has been administered to individuals  
61 deemed to be at high risk for mpox infection. Therefore, the development of a specific serologic assay  
62 to monitor mpox infection is complicated by the vaccination efforts for both smallpox and mpox<sup>9</sup>. The  
63 current serological assay available to detect the presence of OPV-specific antibodies is an ELISA with  
64 formalin-inactivated VAC used as the coating antigen<sup>10-12</sup>. The advantage of a whole-virus assay is the  
65 breadth of OPV antigens available for antibody binding – resulting in a highly sensitive assay. However,  
66 the distinct disadvantage of a whole-virus ELISA is the lack of specificity between OPV species which  
67 may give false-positive results for anyone who has received VAC vaccination. Currently, there is no  
68 approved serology assay that can discriminate between the antibodies produced following vaccination  
69 with VAC versus those mounted upon mpox infection. Therefore, we leveraged a multiplexed

70 microsphere immunoassay (MIA) platform with the goal of maintaining OPV antigenic breadth while  
71 simultaneously gaining specificity to mpox and other non-vaccinia OPVs. In the present study, we  
72 created an algorithm using two mpox-specific peptides and 5 cross-reactive OPV antigens that detects  
73 IgG antibodies associated mpox infection with 93% sensitivity and 98% specificity. Our data support the  
74 use of serology as an important diagnostic tool for mpox infections, and as an mpox surveillance tool  
75 within vaccinated populations.

76

## 77 **Results**

### 78 *Evaluation of Non-Vaccinia Peptides for the Specific Serologic Detection of Mpox Exposure*

79 B21/22R is an immunomodulatory protein present in both mpox and VAR yet absent in VAC,  
80 thus allowing for serologic distinction between VAC vaccination and mpox infection<sup>13, 14</sup>. Dubois et al.  
81 previously reported a peptide-based ELISA using 30-mer peptides optimized for the diagnostic  
82 detection of mpox infection in populations that may include VAC vaccinated individuals. The authors  
83 reported >90% sensitivity and >90% specificity for mpox infection using 4 BSA-conjugated peptides  
84 derived from mpox (B21R-A and -B) and VAR (B22R-A and -B) in a relatively small number of mpox-  
85 positive and -negative subjects<sup>15</sup>. We sought to evaluate efficacy of these previously validated peptides  
86 for the diagnosis of mpox infection on our high-throughput MIA on the Luminex platform. BSA-  
87 conjugated peptides, as described in Dubois et al. were coupled to fluorescent microspheres and  
88 evaluated for IgG reactivity in the mpox-confirmed, mpox-negative, and vaccine control cohorts.  
89 Receiver Operator Characteristic (ROC) analysis revealed moderate predictive accuracy of mpox  
90 infection for mpox-derived B21R-A and -B with an area under the curve (AUC) of 0.86 and 0.85,  
91 respectively. In contrast, VAR-derived peptides B22R-A and -B showed lower predictive accuracy for  
92 mpox infection with AUCs of 0.52 and 0.77, respectively (**Figure 1a; Supplemental Table 1**) and were  
93 eliminated from the diagnostic assay. Based on the sensitivity/specificity calculations generated by the  
94 ROC curve, we calculated clinical cutoff values for mpox peptides B21R-A and -B. Briefly, a Youden's J  
95 index ( $J = \text{sensitivity} + \text{specificity} - 1$ ) was calculated for the range of MFI values in the ROC analysis.  
96 The clinical cutoff was set as the MFI equaling the highest Youden's J index which is equal to the best  
97 balance of specificity and sensitivity over the range of the assay (**Supplemental Table 1**).

98 To visualize the baseline binding IgG reactivity to B21R-A and -B in mpox-negative donors and  
99 recent vaccinees compared to mpox confirmed donors, we plotted the log<sub>10</sub> MFI for individual donors  
100 grouped by cohort as described in Table 1. As routine smallpox vaccination with VAC ended in the  
101 United States in 1972, consideration of birth year allowed us to estimate the childhood vaccination  
102 status of each donor in the mpox-negative cohort<sup>8</sup>. Therefore, mpox-negative donors were divided into  
103 "presumed naïve" and "childhood vaccination" groups based on birth year post- or pre-1972. The

104 average MFI for the mpox-confirmed donors was significantly higher than the presumed naïve,  
105 childhood vaccination, and recent vaccinee groups for both B21R-A and -B (**Figure 1b**). However, a  
106 considerable number of mpox-negative donors show peptide-specific IgG reactivity above the clinical  
107 cutoff despite the lack of mpox exposure. Importantly, the childhood and recent vaccinee groups did not  
108 show higher levels of B21R-A or -B reactivity than the presumed naïve donors indicating that smallpox  
109 vaccination does not contribute to non-specific IgG reactivity to B21R-A and -B in mpox negative  
110 populations. Since up to 57% of mpox cases reported in the 2022 outbreak have been in HIV-positive  
111 individuals<sup>16</sup> we included 142 plasma or serum samples sent to the Wadsworth Center for HIV  
112 confirmatory testing in our mpox-negative cohort. HIV+ donors from the mpox-negative cohort showed  
113 a significantly higher MFI as compared to donors without HIV infection (**Figure 1c**). When considered  
114 together, the specificity of peptides B21R-A and -B (67%; **Supplemental Table 1**) is insufficient for the  
115 development of a robust mpox-specific serological assay.

116

#### 117 *Evaluation of OPV Antigens for the Serologic Detection of Mpox Exposure*

118 We asked whether any naturally cross-reactive recombinant proteins derived from VAC or mpox  
119 could aid in the development of an mpox-specific serologic assay. The predictive accuracy of different  
120 OPV antigens for the detection of mpox infection was tested with a variety of VAC and mpox-derived  
121 protein antigens that were available through a public repository, in-house production, or commercial  
122 vendors. Recombinant proteins VAC A27L, mpox A29L, VAC A33R, mpox A35R, VAC B5R, VAC L1R,  
123 and mpox H3L were tested for IgG antibody reactivity using the same mpox-infection confirmed and  
124 mpox-negative samples as described in Figure 1 (**Figure 2a**). ROC analysis of each antigen revealed  
125 distinct differences in the predictive accuracy for mpox infection. VAC A33R, mpox A35R, VAC B5R,  
126 VAC L1R and mpox H3L showed moderate to excellent predictive accuracy with AUC values above  
127 0.80<sup>17</sup>. In contrast, VAC A27L and homologous mpox A29L showed low predictive accuracy with AUCs  
128 below 0.80 and were removed from the assay. As with the mpox-specific peptides, clinical cutoffs were  
129 calculated for the remaining antigens using the Youden's J index calculated from the ROC analysis.

130 To visualize the baseline binding IgG reactivity to VAC A33R, mpox A35R, VAC B5R, VAC L1R,  
131 and mpox H3L in mpox-negative donors and recent vaccinees as compared to mpox confirmed donors,  
132 we plotted the log<sub>10</sub> MFI for individual donors grouped by cohort as described in Figure 1. The average  
133 MFI of the mpox-confirmed donors for each recombinant antigen was significantly higher than the MFI's  
134 for the mpox-negative presumed naïve and childhood vaccination groups. As expected, the childhood  
135 vaccination group had significantly higher average MFI's than the presumed naïve group indicating  
136 previous exposure to VAC antigens and durable humoral memory from childhood smallpox vaccination  
137 <sup>14, 18</sup> (**Figure 2b**). Although not statistically significant, the average MFI of recent vaccinees trended

138 higher than the childhood vaccination group across all recombinant antigens. These data show that  
139 mpox infection can induce a more robust antibody response than vaccinia vaccination, which may be  
140 exploited for the development of a diagnostic serology assay.

141

#### 142 *Distinct Pattern of IgG Reactivity to OPV Antigens and Mpox-specific Peptides Between Mpox-* 143 *confirmed and Mpox-negative Donors*

144 We asked whether multiplexing multiple antigens would reveal patterns of serological reactivity  
145 that may be used to distinguish between VAC vaccination and mpox infection. To this end, we plotted  
146 each specimen/antigen combination on a heat map to visualize the pattern of reactivity in the mpox-  
147 confirmed and mpox-negative cohorts. The mpox-confirmed donors showed uniform and simultaneous  
148 reactivity to the mpox peptides and the OPV antigens that were tested (**Figure 3**). In contrast, the  
149 mpox-negative presumed naïve group showed sporadic reactivity to the mpox peptides and OPV  
150 antigens. Here, individuals that showed positive reactivity to the B21R peptides did not show  
151 simultaneous reactivity with the OPV antigens. The mpox-negative childhood vaccination group  
152 displayed an increased frequency of antigen reactivity as expected with previous exposure to VAC, yet  
153 rarely showed simultaneous reactivity to the mpox peptides and OPV antigens. Recent vaccinees  
154 displayed a similar pattern of mpox peptide and OPV antigen reactivity to the childhood vaccination  
155 group. The differential patterns of antigen reactivity between mpox-confirmed and mpox-negative  
156 cohorts suggest a combination of OPV antigens and mpox-specific peptides may provide specific  
157 serologic detection of mpox infection.

158

#### 159 *Development of an Algorithm for the Specific Detection of Mpox Infection*

160 With the goal of developing an algorithm for a mpox-specific assay we counted the number of  
161 clinically reactive (MFI above the clinical cutoff) OPV antigens for every individual in the mpox-  
162 confirmed and -negative cohorts. Donors from the mpox-confirmed cohort were simultaneously reactive  
163 for at least 3 OPV antigens, with a median count of 4 antigens (**Figure 4a**). In contrast, presumed  
164 naïve donors from the mpox-negative cohort were rarely reactive for 1 OPV antigen with a median  
165 count of 0 antigens. Mpox-negative donors from the childhood vaccination and recent vaccinee groups  
166 showed a range of reactivity from 0 to 4 OPV antigens with median counts of 0 and 2.0, respectively.  
167 Setting a clinical cutoff of 3 or more reactive antigens captures 98% of the mpox-confirmed donors  
168 while excluding 95% of the mpox-negative cohort.

169 Based on the high antibody reactivity of mpox-infected donors to both cross reactive OPV  
170 antigens and the mpox-specific peptides, we developed a two-tiered algorithm designed to remove  
171 individuals without true mpox infection from further analysis (**Figure 4b**). First, the total number of

172 reactive (MFI  $\geq$  cutoff) OPV antigens (A33/35R, B5R, L1R, H3L) was counted for each individual donor.  
173 Donors with less than 3 reactive OPV antigens will automatically be considered negative (non-reactive;  
174 NR) for mpox-infection. Donors with 3 or more reactive OPV antigens will be considered for the next  
175 step of the algorithm. At this stage 95% of the mpox-negative donors (n=341) have been labeled NR  
176 and removed from the analysis, while 98% of the mpox-infected cohort will move to the next tier of the  
177 algorithm. Next, donors that “passed” the first step of the algorithm will be considered for IgG reactivity  
178 to the mpox-specific peptides B21R-A and -B. Finally, donor samples that are reactive (MFI  $\geq$  cutoff) for  
179 one or both peptides will be considered positive (reactive; R) for mpox infection. After the second step  
180 of the algorithm 37 out of 40 patients from the mpox-confirmed cohort have been labelled R, giving our  
181 diagnostic test (New York State Orthopoxvirus Non-Vaccinia Virus Microsphere Immunoassay for IgG  
182 Antibody Detection; NYS-OPV-MIA) 93% (95%CI = 80-97%) sensitivity for mpox infection with an  
183 overall specificity of 98% (95%CI = 96-99%) (**Table 3**). It is important to note that assay specificity is  
184 different depending on the test population. When testing vaccinated donors assay specificity is 94%  
185 (95%CI = 88-97%) for the childhood vaccinee group, and 93% (95%CI = 88-96%) when the recent  
186 vaccinees are added to the calculation. However, the NYS-OPV-MIA is highly (100%; 98-100%)  
187 specific when testing unvaccinated individuals under 50 years of age. As part of assay validation we  
188 also tested a specificity panel of 115 serum specimens with known antibodies to a diverse group of  
189 bacterial and viral pathogens, as well as anti-nuclear antibodies (ANA) and rheumatoid factor (RF)  
190 (Supplemental Table 1). The specificity panel included specimens from infections that may be confused  
191 with mpox, including Syphilis (n=8), Herpes Simplex Virus (HSV; n = 15), and Varicella Zoster (n = 18).  
192 When combined with the mpox-negative cohort (n = 456) the specificity of the NYS-OPV-MIA remains  
193 at 98% (95%CI = 96-99%). In summary, we have developed a robust serological assay with high  
194 sensitivity and high specificity to aid in the diagnosis of mpox-infection.

### 195 196 *Strength of Mpox Antigen Binding is Dictated by the First Viral Exposure*

197 The induction of potent cross-protective immunity through vaccinia virus vaccination for  
198 protection against smallpox is well established<sup>19, 20</sup>. There is also strong evidence for VAC vaccination  
199 to provide some degree of protection against mpox infection<sup>21, 22</sup>. Our mpox serology assay includes the  
200 homologous proteins A33/35R from both VAC and mpox respectively, which allowed us to ask how  
201 previous exposure to VAC through vaccination influences antibody binding following mpox infection. To  
202 this end, we divided the mpox cohort by birth year to reflect the childhood vaccination status of the  
203 mpox-positive cohort. When considering IgG binding to VAC A33R, mpox-infected patients bind equally  
204 well to VAC A33R regardless of previous VAC exposure. In contrast, mpox-infected patients under 50  
205 trended toward higher binding to mpox A35R as compared to their previously vaccinated counterparts

206 **(Figure 4c)**. To estimate the relative binding of VAC A33R versus mpox A35R in each antigen  
207 exposure group we calculated a binding ratio by dividing the IgG MFI of VAC A33R by the IgG MFI of  
208 mpox A35R. The resulting data revealed differential binding of the A33/35R homologues based on the  
209 primary immunizing virus. The vaccine control group showed the highest VAC/mpox binding ratio  
210 indicating that antibodies from this group bound the VAC A33R protein better than the mpox  
211 homologue. In contrast, previously unvaccinated mpox-infected patients showed the lowest binding  
212 ratio, indicating better antibody binding to mpox A35R rather than the VAC homologue. Interestingly,  
213 previously vaccinated mpox-infected patients showed an intermediate A33/35R binding ratio suggesting  
214 a contribution from both VAC-derived and mpox-derived antibodies to the overall binding profile in  
215 these patients. Together these data demonstrate the presence of distinct epitopes in homologous  
216 proteins despite high levels of cross-reactivity, and that original antigenic sin may play a role in the  
217 humoral response to mpox in previously vaccinated individuals.

218

## 219 **Discussion**

220 In response to a Public Health Emergency of International Concern, we developed a sensitive  
221 (93%) and specific (98%) multiplex MIA for the differential serologic detection of mpox infection in VAC  
222 vaccinated populations. The assay contains 2 mpox-specific peptides and 5 cross-reactive OPV  
223 recombinant proteins derived from either VAC or mpox. Here, we leveraged both multiplex technology  
224 and the differential antibody reactivity profiles resulting from VAC vaccination and mpox infection to  
225 build specificity into our serologic assay.

226 In 2012 Slifka and colleagues reported a highly sensitive mpox-specific ELISA based on 30-mer  
227 peptides derived from the B21/22R gene that is present in mpox yet absent in VAC<sup>15</sup>. We tested the  
228 BSA-conjugated B21/22R peptides on our multiplex MIA as a high-throughput alternative to the  
229 previously described ELISA. Of the four peptides tested, mpox-derived B21R-A and -B had the best  
230 discriminatory capacity for mpox infection, where VAR-derived B22R-A and -B were comparatively  
231 poor. In contrast to the Dubois-Slifka study, we found extensive non-specific IgG reactivity to the  
232 peptides in an mpox-negative population, the origin of which is unknown. The most likely explanation  
233 for the discrepant specificity between studies is the size and composition of our negative cohort. The  
234 mpox-negative cohort of the Dubois-Slifka study was composed of 20 healthy naïve, recently  
235 vaccinated, and childhood vaccinated donors for a total of 60 test subjects. Here, we calculated  
236 diagnostic specificity of the B21/22R peptides based on a negative cohort of 341 donors, 142 of which  
237 were HIV-positive. A thorough analysis of our mpox-negative cohort revealed that much of the non-  
238 specific reactivity seen to the peptides was present in the samples collected from people living with  
239 HIV. In fact, non-specific serologic reactivity in HIV+ populations due to polyclonal B cell activation and



240 hypergammaglobulinemia is a well-characterized aspect of HIV infection<sup>23, 24</sup>. Further, many HIV-1-  
241 specific broadly neutralizing antibodies generated during HIV infection are polyreactive<sup>25</sup>. The high  
242 frequency of HIV+ patients in the mpox test population<sup>16</sup> has the potential to impact assay performance  
243 and underscores the importance of considering test population demographics prior to assay  
244 development. In addition, we clearly demonstrated that the B21/22R-derived peptides tested here had  
245 insufficient specificity to be used as a stand-alone diagnostic assay.

246 With a lack of additional non-vaccinia derived proteins to test, we turned to immunodominant  
247 VAC and mpox antigens known for their cross-reactivity across OPV species. We demonstrate that  
248 mpox-infected donors have robust IgG reactivity to the immunodominant antigens A33/35R, B5R, L1R,  
249 and H3L. In contrast, both recent and childhood vaccinees show detectable antibody reactivity to one or  
250 more of the antigens tested, while the antibody profile of each individual lacks the magnitude and  
251 antigenic breadth that is seen following mpox infection. Our data is supported by previous work  
252 showing the majority of VAC vaccinees recognize a small fraction of the OPV proteins tested in a  
253 protein microarray. Moreover, no single antigen in the array was universally recognized by all  
254 vaccinees<sup>12</sup>. Further, antibodies specific for immunodominant antigens A33, B5, L1, and H3 are rarely  
255 seen in all individuals following primary VAC immunization<sup>12, 26, 27</sup>. The cause for reduced antibody titer  
256 and antigenic breadth in vaccinated versus mpox infected individuals may be due to differences in viral  
257 load or tropism that occur through vaccination versus infection<sup>28</sup>. In fact, challenge models have shown  
258 increases in both the magnitude and coverage of OPV-specific antibodies following mpox infection of  
259 VAC vaccinated animals<sup>12</sup>.

260 Serologic assays measure the host response to an infectious agent which can be detected for  
261 months to years following infection. However, measuring the host immune response comes with  
262 inherent challenges such as antigenic cross-reactivity and genetic variability between individuals. We  
263 demonstrated that a multiplex immunoassay platform using a combination of mpox peptides and OPV  
264 proteins can identify mpox infection with high sensitivity and specificity in a population where VAC  
265 vaccination has occurred. Furthermore, we show that mpox infection and VAC vaccination result in  
266 differential patterns of IgG reactivity that could be exploited for diagnostic detection despite high levels  
267 of antigenic cross-reactivity. The bead-based platform described in this study is amenable to high-  
268 throughput processing which may be useful for performing large-scale sero-epidemiology studies<sup>29</sup> in  
269 high-risk populations and inform our understanding of mpox transmission in the future.

## 270 **Limitations of the Study**

271 The B21/22R gene is present used as the final discriminator for mpox infection in our assay is  
272 expressed in other non-vaccinia OPV species. Interpretation of our assay may be difficult in regions  
273 where cowpox or other non-vaccinia OPVs are endemic<sup>30</sup>. In addition, sequencing efforts during the  
274 2002 mpox outbreak have identified isolates with genetic deletions that may affect the B21R gene<sup>31</sup>.  
275 B21R deletions in the mpox genome have the potential to effect assay sensitivity if such mutations  
276 were to be commonplace in circulating mpox strains.

## 277 **Acknowledgements**

278 We wish to acknowledge and express our gratitude to all of the study participants for their generosity,  
279 without which this study would not be possible. We acknowledge and thank the following members of the  
280 Diagnostic Immunology Laboratory for their expert technical assistance: Kelly Howard, Kyle Carson,  
281 and Theresa Lamson. We acknowledge and thank Jean Rock and Rachel Bievenue of the Bloodborne  
282 Viruses Laboratory and Michael Perry of the Biodefense Laboratory for providing sample preparation.  
283 We acknowledge and thank Heidi Dillenbeck for quality control and quality assurance support. We  
284 thank Archana Thomas of the Slifka Laboratory for assistance with sample preparation and shipping.  
285 We thank Dr. Charles Gonzalez of the AIDS Institute, NYSDOH for facilitating serum specimen  
286 acquisition. We thank Nicholas J. Mantis for critical reading of the manuscript. Peptides were  
287 manufactured and supplied by Aalto Bio Reagents, Biosynth Group.

288

## 289 *Funding Sources*

290 This (publication, journal article, etc.) was supported by Cooperative Agreement Number  
291 NU50CK000516 funded by the Centers for Disease Control and Prevention. Its contents are solely the  
292 responsibility of the authors and do not necessarily represent the official views of the Centers for  
293 Disease Control and Prevention or the Department of Health and Human Services. V.S. and her team  
294 are, in part, supported by U19AI168621 and seed funds of the Mount Sinai Vaccine Research and  
295 Pandemic Preparedness (c-VaRPP).

296

## 297 **Author Contributions Statement**

298 **Conceptualization**, J.L.Y., W.T.L., M.K.S.; **Methodology**, D.T.H., J.L.Y.; **Validation**, D.T.H., K.E.K.;  
299 **Formal Analysis**, J.L.Y. **Investigation**, D.T.H., J.L.Y.; **Resources**, K.C., L.S., S.T.C., G.Y.C., M.C.B-  
300 G., G.K., D.A., K.S., P.V.I., V.S., D.F., J.M., W.H., P.N., C.E., M.K.S.; **Data Curation**, J.L.Y., D.T.H.  
301 **Writing – Original Draft**, J.L.Y.; **Writing – Review and Editing**, J.L.Y., M.K.S., W.T.L and N.J.M.;  
302 **Visualization**, J.L.Y.; **Supervision**, W.T.L., M.K.S., and J.L.Y.

303

## 304 **Declaration of Interests**

305 P.K. and W.H. have a financial interest in Aalto Bio Reagents, a company that may have a commercial  
306 interest in the results of this research and technology. OHSU and M.K.S. have a financial interest in  
307 Najit Technologies, Inc., a company that may have a commercial interest in the results of this research  
308 and technology. This potential individual and institutional conflict of interest has been reviewed and  
309 managed by OHSU. The Icahn School of Medicine at Mount Sinai has filed patent applications relating  
310 to SARS-CoV-2 serological assays, which list Viviana Simon as a co-inventor.

311 **Figure Legends**

312

313 **Figure 1: Evaluation of Non-Vaccinia Peptides for the Detection of Mpox Infection**

314

315 Serum or plasma specimens from 341 presumed mpox-negative donors and 40 mpox confirmed  
316 patients were analyzed for antibody reactivity to peptide antigens derived from mpox and variola virus  
317 (VAR) by a microsphere immunoassay. **(A)** Median fluorescence intensity (MFI) of IgG reactivity to  
318 individual 31-mer peptides was used to generate ROC curves representing for mpox-derived B21R-A  
319 and -B (magenta) or VAR-derived B22R-A and -B (blue). **(B)** The  $\log_{10}$  MFI of IgG reactivity to mpox  
320 B21R-A and -B was plotted for mpox-negative, -positive, and recent vaccinee donors. The mpox-  
321 negative cohort was divided by birth year post- and pre-1972 to estimate smallpox childhood  
322 vaccination status. **(C)**  $\log_{10}$  MFI of IgG reactivity to mpox B21R-A and -B was plotted for mpox-  
323 negative donors post-1972 (>50) divided by “healthy” and “HIV”. Each dot represents an individual  
324 donor. Statistical significance was determined by the non-parametric Kruskal-Wallis test where \* $p <$   
325 0.05 \*\* $p <$  0.001 \*\*\* $p <$  0.0001, and \*\*\*\* $p <$  0.00001 adjusted for multiple comparisons by Dunn's test.

326

327 **Figure 2: IgG Antibody Reactivity to Orthopoxvirus Antigens Among Mpox Negative and**  
328 **Positive Cohorts**

329 Serum or plasma specimens from 341 presumed mpox-negative donors and 40 mpox confirmed  
330 patients were analyzed for antibody reactivity to recombinant protein antigens derived from mpox or  
331 vaccinia virus (VAC) by microsphere immunoassay. **(A)** Median fluorescence intensity (MFI) of IgG  
332 reactivity to recombinant antigens from mpox or VAC (mpox A35R, solid magenta; VAC A33R, dashed  
333 magenta; mpox H3L solid light blue; VAC B5R dashed green; VAC L1R dashed orange; mpox A29L  
334 solid dark blue, VAC A27L dashed dark blue) were used to generate ROC curves used to represent the  
335 sensitivity (%) and specificity (%) of each antigen to detect mpox infection. **(B)**  $\log_{10}$  MFI of IgG  
336 reactivity to OPV antigens (A33/35, B5R, L1R, and H3L) plotted for mpox-negative, -positive, and  
337 recent vaccinee donors. Each dot represents an individual donor. Statistical significance was  
338 determined by the non-parametric Kruskal-Wallis test where \* $p <$  0.05 \*\* $p <$  0.001 \*\*\* $p <$  0.0001, and  
339 \*\*\*\* $p <$  0.00001 adjusted for multiple comparisons by Dunn's test.

340

341 **Figure 3: Pattern of OPV Antigen and Mpox Peptide IgG Reactivity Among Mpox-negative and -**  
342 **positive Cohorts**

343 Heat maps indicate the relative index value (MFI/cutoff value) of each antigen (Mpox A35R, VAC B5R,  
344 VAC L1R, Mpox H3L, Mpox B21R-A, and Mpox B21R-B; vertical columns) for each serum/plasma

345 donor (horizontal rows). Yellow corresponds to a negative index value ( $< 1.0$ ) below the clinical cutoff.  
346 The level of red saturation corresponds to higher index values ( $> 1.0$ ) above the clinical cutoff.

347

348 **Figure 4: OPV Antigen Count and Algorithm for the Specific Serologic Detection of Mpox**  
349 **Infection**

350 **(A)** The number of OPV antigens (A33/35, B5R, L1R, and H3L) counted as reactive (R). Reactivity was  
351 defined as an MFI value at or above the calculated clinical cutoff value. The antigen count distribution  
352 was displayed as a violin plot for mpox-confirmed and mpox-negative cohorts. The mpox-negative  
353 cohort divided by birth year post- (presumed naïve) and pre-1972 (Childhood VAC) to estimate  
354 smallpox childhood vaccination status. **(B)** Serum or plasma specimens tested for mpox infection using  
355 a multiplexed microsphere immunoassay will be subjected to a 2-tier algorithm using a combination of  
356 mpox-specific peptides and OPV antigens. First, specimens will be considered for IgG reactivity to a set  
357 of cross-reactive OPV antigens (VAC A33R, mpox A35R, VAC B5R, VAC L1R, and mpox H3L).  
358 Samples with reactivity to 2 or fewer antigens will be considered non-reactive (NR;  $\text{MFI} < \text{clinical cutoff}$ )  
359 overall for mpox exposure while samples that test reactive (R;  $\text{MFI} > \text{clinical cutoff}$ ) to 3 or more OPV  
360 antigens will move to the second tier of the algorithm. Next, samples will be considered for their  
361 reactivity to mpox peptides B21R-A and -B. Samples with no peptide reactivity will be considered NR  
362 for mpox infection. Samples with reactivity to one or more mpox peptides will be considered R for mpox  
363 infection. **(C)** Serum specimens from mpox-confirmed donors ( $n=40$ ) and recent vaccinees ( $n=15$ ) were  
364 analyzed for IgG reactivity to viral homologues VAC A33R and mpox A35R. Mpox confirmed donors  
365 were separated by birth year to simulate vaccination status before infection. Green circles indicate  
366 recent vaccinees. Grey circles indicate a birth year prior to 1972 (childhood vaccine), and blue circles  
367 indicate a birth year after 1972 (unvaccinated). Red circles in both groups indicate individuals infected  
368 in the 2003 mpox outbreak. The dashed line in each plot indicates the reactivity cutoff for the indicated  
369 antigen as determined by ROC curve. **(D)** Serum IgG reactivity ratio representing the mpox A35R MFI  
370 divided by the VAC A33R MFI. Green circles indicate recent vaccinees. Grey circles indicate a birth  
371 year prior to 1972 (childhood vaccine), and blue circles indicate a birth year after 1972 (unvaccinated).  
372 Red circles in both groups indicate individuals infected in the 2003 mpox outbreak. Statistical  
373 significance was determined by the non-parametric Kruskal-Wallis test where  $*p < 0.05$   $**p < 0.001$   $***p$   
374  $< 0.0001$ , and  $****p < 0.00001$  adjusted for multiple comparisons by Dunn's test.

375

376

377  
378  
379  
380  
381  
382  
383  
384  
385  
386  
387  
388  
389  
390  
391  
392  
393  
394  
395  
396  
397  
398  
399  
400  
401  
402  
403  
404  
405  
406  
407  
408  
409  
410  
411  
412  
413  
414  
415  
416  
417  
418  
419  
420  
421  
422  
423  
424  
425  
426  
427

## Main Text References

1. Rimoin AW, KISALU N, Kebela-Ilunga B, Mukaba T, Wright LL, Formenty P, Wolfe ND, Shongo RL, Tshioko F, Okitolonda E, et al. (2007). Endemic human monkeypox, Democratic Republic of Congo, 2001-2004. *Emerg Infect Dis* 13, 934-937. 2007/06/08.
2. Rimoin AW, Mulembakani PM, Johnston SC, Lloyd Smith JO, Kisalu NK, Kinkela TL, Blumberg S, Thomassen HA, Pike BL, Fair JN, et al. (2010). Major increase in human monkeypox incidence 30 years after smallpox vaccination campaigns cease in the Democratic Republic of Congo. *Proc Natl Acad Sci U S A* 107, 16262-16267. 2010/09/02.
3. Huang Y, Mu L and Wang W. (2022). Monkeypox: epidemiology, pathogenesis, treatment and prevention. *Signal Transduct Target Ther* 7, 373. 2022/11/03.
4. Yinka-Ogunleye A, Aruna O, Dalhat M, Ogoina D, McCollum A, Disu Y, Mamadu I, Akinpelu A, Ahmad A, Burga J, et al. (2019). Outbreak of human monkeypox in Nigeria in 2017-18: a clinical and epidemiological report. *Lancet Infect Dis* 19, 872-879. 2019/07/10.
5. Gross E. (2003). Update on emerging infections: news from the Centers for Disease Control and prevention. Update: Multistate outbreak of monkeypox--Illinois, Indiana, Kansas, Missouri, Ohio, and Wisconsin, 2003. *Ann Emerg Med* 42, 660-662; discussion 662- 664. 2003/10/29.
6. Hendrickson RC, Wang C, Hatcher EL and Lefkowitz EJ. (2010). Orthopoxvirus genome evolution: the role of gene loss. *Viruses* 2, 1933-1967. 2011/10/14.
7. Grabenstein JD and Winkenwerder W, Jr. (2003). US military smallpox vaccination program experience. *JAMA* 289, 3278-3282. 2003/06/26.
8. Henderson DA, Inglesby TV, Bartlett JG, Ascher MS, Eitzen E, Jahrling PB, Hauer J, Layton M, McDade J, Osterholm MT, et al. (1999). Smallpox as a biological weapon: medical and public health management. Working Group on Civilian Biodefense. *JAMA* 281, 2127-2137. 1999/06/15.
9. Payne AB, Ray LC, Cole MM, Canning M, Houck K, Shah HJ, Farrar JL, Lewis NM, Fothergill A, White EB, et al. (2022). Reduced Risk for Mpox After Receipt of 1 or 2 Doses of JYNNEOS Vaccine Compared with Risk Among Unvaccinated Persons - 43 U.S. Jurisdictions, July 31-October 1, 2022. *MMWR Morb Mortal Wkly Rep* 71, 1560-1564. 2022/12/09.
10. Karem KL, Reynolds M, Hughes C, Braden Z, Nigam P, Crotty S, Glidewell J, Ahmed R, Amara R and Damon IK. (2007). Monkeypox-induced immunity and failure of childhood smallpox vaccination to provide complete protection. *Clin Vaccine Immunol* 14, 1318-1327. 2007/08/24.
11. Priyamvada L, Carson WC, Ortega E, Navarra T, Tran S, Smith TG, Pukuta E, Muyamuna E, Kabamba J, Nguete BU, et al. (2022). Serological responses to the MVA-based JYNNEOS monkeypox vaccine in a cohort of participants from the Democratic Republic of Congo. *Vaccine* 40, 7321-7327. 2022/11/08.
12. Townsend MB, Keckler MS, Patel N, Davies DH, Felgner P, Damon IK and Karem KL. (2013). Humoral immunity to smallpox vaccines and monkeypox virus challenge: proteomic assessment and clinical correlations. *J Virol* 87, 900-911. 2012/11/09.
13. Alzhanova D, Hammarlund E, Reed J, Meermeier E, Rawlings S, Ray CA, Edwards DM, Bimber B, Legasse A, Planer S, et al. (2014). T cell inactivation by poxviral B22 family proteins increases viral virulence. *PLoS Pathog* 10, e1004123. 2014/05/17.
14. Hammarlund E, Lewis MW, Hansen SG, Strelow LI, Nelson JA, Sexton GJ, Hanifin JM and Slifka MK. (2003). Duration of antiviral immunity after smallpox vaccination. *Nat Med* 9, 1131-1137. 2003/08/20.
15. Dubois ME, Hammarlund E and Slifka MK. (2012). Optimization of peptide-based ELISA for serological diagnostics: a retrospective study of human monkeypox infection. *Vector Borne Zoonotic Dis* 12, 400-409. 2012/01/06.
16. Kava CM, Rohraff DM, Wallace B, Mendoza-Alonzo JL, Currie DW, Munsey AE, Roth NM, Bryant-Genevier J, Kennedy JL, Weller DL, et al. (2022). Epidemiologic Features of the Monkeypox Outbreak and the Public Health Response - United States, May 17-October 6, 2022. *MMWR Morb Mortal Wkly Rep* 71, 1449-1456. 2022/11/11.

- 428 17. Mandrekar JN. (2010). Receiver operating characteristic curve in diagnostic test assessment. *J*  
429 *Thorac Oncol* 5, 1315-1316. 2010/08/26.
- 430 18. Crotty S, Felgner P, Davies H, Glidewell J, Villarreal L and Ahmed R. (2003). Cutting edge:  
431 long-term B cell memory in humans after smallpox vaccination. *J Immunol* 171, 4969-4973. 2003/11/11.
- 432 19. Hanna W and Baxby D. (2002). Studies in smallpox and vaccination. 1913. *Rev Med Virol* 12,  
433 201-209. 2002/07/19.
- 434 20. Gilchuk I, Gilchuk P, Sapparapu G, Lampley R, Singh V, Kose N, Blum DL, Hughes LJ,  
435 Satheshkumar PS, Townsend MB, et al. (2016). Cross-Neutralizing and Protective Human Antibody  
436 Specificities to Poxvirus Infections. *Cell* 167, 684-694 e689. 2016/10/22.
- 437 21. Hammarlund E, Lewis MW, Carter SV, Amanna I, Hansen SG, Strelow LI, Wong SW, Yoshihara  
438 P, Hanifin JM and Slifka MK. (2005). Multiple diagnostic techniques identify previously vaccinated  
439 individuals with protective immunity against monkeypox. *Nat Med* 11, 1005-1011. 2005/08/09.
- 440 22. Earl PL, Americo JL, Wyatt LS, Eller LA, Whitbeck JC, Cohen GH, Eisenberg RJ, Hartmann CJ,  
441 Jackson DL, Kulesh DA, et al. (2004). Immunogenicity of a highly attenuated MVA smallpox vaccine  
442 and protection against monkeypox. *Nature* 428, 182-185. 2004/03/12.
- 443 23. Lane HC, Masur H, Edgar LC, Whalen G, Rook AH and Fauci AS. (1983). Abnormalities of B-  
444 cell activation and immunoregulation in patients with the acquired immunodeficiency syndrome. *N Engl*  
445 *J Med* 309, 453-458. 1983/08/25.
- 446 24. Shirai A, Cosentino M, Leitman-Klinman SF and Klinman DM. (1992). Human immunodeficiency  
447 virus infection induces both polyclonal and virus-specific B cell activation. *J Clin Invest* 89, 561-566.  
448 1992/02/01.
- 449 25. Prigent J, Jarossay A, Planchais C, Eden C, Dufloo J, Kok A, Lorin V, Vratskikh O, Couderc T,  
450 Bruel T, et al. (2018). Conformational Plasticity in Broadly Neutralizing HIV-1 Antibodies Triggers  
451 Polyreactivity. *Cell Rep* 23, 2568-2581. 2018/05/31.
- 452 26. Duke-Cohan JS, Wollenick K, Witten EA, Seaman MS, Baden LR, Dolin R and Reinherz EL.  
453 (2009). The heterogeneity of human antibody responses to vaccinia virus revealed through use of  
454 focused protein arrays. *Vaccine* 27, 1154-1165. 2009/01/17.
- 455 27. Lantto J, Haahr Hansen M, Rasmussen SK, Steinaa L, Poulsen TR, Duggan J, Dennis M,  
456 Naylor I, Easterbrook L, Bregenholt S, et al. (2011). Capturing the natural diversity of the human  
457 antibody response against vaccinia virus. *J Virol* 85, 1820-1833. 2010/12/15.
- 458 28. Yefet R, Friedel N, Tamir H, Polonsky K, Mor M, Cherry-Mimran L, Taleb E, Hagin D, Sprecher  
459 E, Israely T, et al. (2023). Monkeypox infection elicits strong antibody and B cell response against  
460 A35R and H3L antigens. *iScience* 26, 105957. 2023/01/24.
- 461 29. Styer LM, Hoen R, Rock J, Yauney E, Nemeth K, Bievenue R and Parker MM. (2021). High-  
462 Throughput Multiplex SARS-CoV-2 IgG Microsphere Immunoassay for Dried Blood Spots: A Public  
463 Health Strategy for Enhanced Serosurvey Capacity. *Microbiol Spectr* 9, e0013421. 2021/07/29.
- 464 30. Reynolds SE and Moss B. (2015). Characterization of a large, proteolytically processed cowpox  
465 virus membrane glycoprotein conserved in most chordopoxviruses. *Virology* 483, 209-217. 2015/05/20.
- 466 31. Sereewit J, Lieberman NAP, Xie H, Bakhash S, Nunley BE, Chung B, Mills MG, Roychoudhury  
467 P and Greninger AL. (2022). ORF-Interrupting Mutations in Monkeypox Virus Genomes from  
468 Washington and Ohio, 2022. *Viruses* 14. 2022/11/12.
- 469

470 **Materials and Methods**

471

472 **Experimental Model and Subject Details**

473 ***Human Subjects***

474 This assay development study was performed using deidentified sera and plasma for a public health  
475 function in a declared Public Health Emergency (PHE). It has been deemed “Non-human subject  
476 research” by the NYS Institutional Review Board.

477 Biospecimens provided by the Icahn School of Medicine at Mount Sinai from the Personalized Virology  
478 Initiative were reviewed and approved by the Mount Sinai Hospital Institutional Review Board (IRB-16-  
479 16772 and IRB-16-00791). All participants provided written informed consent before specimens and  
480 clinical information were collected. All specimens were coded before processing and analysis.

481 ***Specimen Collection***

482 Whole blood in a red top/SST or equivalent tube, specimens allowed to clot at room temperature,  
483 centrifuged and transferred serum into plastic tube(s), with storage refrigerated at 2-8°C prior to  
484 shipment on freezer

485 ***Mpox-Negative Cohort***

486 *Healthy-Normal*

487 Wadsworth Center employees volunteered serum specimens for assay development (n=114); 59 were  
488 born prior to 1972 and 55 born after 1972. Normal Healthy Serum Pre-COVID-19 Pandemic Panel E  
489 was purchased from Access Biologicals (n=85); 85 were born prior to 1972 and 66 born after 1972 with  
490 military status unknown.

491 *HIV+*

492 One hundred and forty-three (142) remnant plasma and serum specimens submitted for HIV  
493 diagnostic testing to the Wadsworth Center between 1/1/2018 and 12/31/2021. Specimens were  
494 submitted for a variety of reasons, including confirmation of a reactive result on an HIV rapid test, to  
495 resolve discordant HIV test results, or to verify a previous HIV diagnosis. HIV status was ‘HIV-1  
496 antibody positive for 131 (92%) and ‘HIV antibody negative for 12 (8%) of the specimens. Specimens  
497 were collected from individuals born either prior to 1972 (n=42) or after 1980 (n=100).

498 ***Mpox-Confirmed Cohort***

499 The mpox-confirmed cohort (n = 40) is composed of specimens collected during the 2003 and 2022  
500 United States outbreaks (**Table 1; Supplemental Figure 1**).

501 *2003 Outbreak*

502 Eighteen (18) of the 40 samples were collected following the 2003 mpox outbreak in the United States  
503 at approximately 6 months post-infection as previously described<sup>21</sup>. Eight out of 18 donors (44%)



504 received childhood smallpox immunization. The 2003 cohort was 66% female with an average age of  
505 33 years at serum collection<sup>21</sup>.

#### 506 2022 Outbreak

507 Twenty-two (22) of the 40 samples were collected during the 2022 mpox outbreak. In total, the group  
508 was 90% male with an average age of 40 years at specimen collection.

509 Two (2) serum specimens were submitted to the Wadsworth Center Biodefense Laboratory for mpox  
510 diagnostic testing on days 9 and 15 post-symptom onset, respectively. Mpox diagnosis was confirmed  
511 by PCR assay.

512 At the Zucker School of Medicine at Hofstra/Northwell, serum was collected from 13 persons with  
513 confirmed mpox infection, as defined by a positive PCR assay result. Specimens were de-identified and  
514 the data collected included age, gender, date of mpox symptom onset, date of PCR positive test, name  
515 of PCR assay used, VAC vaccination history, and date of serum collection.

516 At the Icahn School of Medicine at Mt. Sinai, serum was collected from 7 persons with confirmed mpox  
517 infection by PCR assay. Specimens were de-identified and the shared data included age range,  
518 gender, days since symptom onset, and VAC vaccination history.

#### 519 ***Recent Vaccinee Cohort***

520 The vaccinee cohort is composed of 5 serum specimens from Wadsworth Center employee donors  
521 who were vaccinated with JYNNEOS® (day 56 post-primary inoculation), and 10 serum specimens  
522 provided by donors from The Icahn School of Medicine at Mt. Sinai that were vaccinated with  
523 JYNNEOS® (n=8) or ACAM 2000 (n=2). All serum specimens used for analysis were collected at least  
524 20 days following the last dose of vaccine.

525

#### 526 **Expression, Production, and Purification of Antigens**

##### 527 ***Production of B21/22R Peptides***

528 Peptides were manufactured and supplied by Aalto Bio Reagents, Biosynth Group. The sequences for  
529 peptides MPV B21R-A and -B, and VM B22R-A and B, were described in Dubois et. al.<sup>15</sup> MPV B21R-A  
530 and B correspond to B21R.179/180 and B21R.185/186, respectively. VM B22R-A and B correspond to  
531 B22R.64/65 and B22R.82/83, respectively. Peptide produced using standard Fmoc-based solid phase  
532 synthesis and purified using reverse phase high-performance liquid chromatography (RP-HPLC) to  
533 >90% pure as determined by HPLC and/or LC/MS. Conjugation to BSA occurred through the side chain  
534 of cysteine via sylvhydryl chemistry by mixing peptides with maleimide-activated BSA for two hours at  
535 room temperature.

536

##### 537 ***Recombinant OPV Antigens***

538 Recombinant proteins were obtained from several commercial sources. Recombinant A27L (VAC-WR-  
539 A27L; NR 2213), A33R (VAC-WR-A33R; NR545), B5R (VAC-WR-B5R; NR-546) and L1R (VAC-WR-  
540 L2R; NR-21986) were obtained from BEI Resources, Manassas VA. Recombinant mpox A35R (230-  
541 30238) and mpox H3L (230-30233) were purchased from Ray Biotech, Peachtree Corners, GA. Mpox  
542 A29L was produced by the Wadsworth Center Protein Expression Core. The mpox A29L gene  
543 (GenBank: AY160186) subcloned into the plasmid pETMPOX/A27Lo-His6 was obtained from bei  
544 Resources (Catalog # NR-3022). The construct was transformed into BL21(DE3)pLysS (Novagen) and  
545 expressed in Luria Broth containing 30 µg/mL kanamycin. Cell pellets were lysed in 50 mM Tris HCl,  
546 300 mM NaCl, 10 mM imidazole, 0.1% Triton X100, 10% sucrose pH 7.5 containing EDTA-free  
547 Complete Protease inhibitor (Roche) and 50 U Benzonase (Novagen). Cleared lysate was applied to a  
548 1 ml HisTrap HP column (Cytiva) in 50 mM Tris HCl, 150 mM NaCl, 10% glycerol pH 7.5, washed with  
549 50 mM Tris HCl, 1 M NaCl, 0.25 M arginine pH 8.5, and eluted with a linear gradient over 20 column  
550 volumes to 50 mM Tris HCl, 150 mM NaCl, 10% glycerol, 500 mM imidazole pH 7.5. Fractions  
551 containing protein were pooled and dialyzed against 50 mM Tris HCl, 150 mM NaCl, 10% glycerol, 1  
552 mM EDTA pH 7.5 and then twice against a large excess of phosphate-buffered saline (PBS). The  
553 protein was checked for size (16.4 kDa) and purity by sodium dodecyl sulfate polyacrylamide  
554 electrophoresis (SDS-PAGE).

555

556 ***OPV-specific Multiplex Microsphere Immunoassay (MIA)***

557 Specimens were assessed for the presence of antibodies reactive to OPV antigens using an MIA.  
558 Recombinant proteins were covalently linked to the surface of fluorescent, magnetic microspheres  
559 (Luminex Corporation). Serum or plasma samples (25 µl at 1:100 dilution) and antigen-coupled  
560 microspheres (25 µl at  $5 \times 10^4$  microspheres/mL) were mixed and incubated for 30 minutes at 37°C.  
561 Serum-bound microspheres were washed and incubated with phycoerythrin (PE)-conjugated secondary  
562 antibody specific for human IgG (Southern Biotech). After washing and final resuspension in buffer, the  
563 samples were analyzed on a FlexMap 3D analyzer using xPONENT software, version 4.3 (Luminex  
564 Corporation).

**Table 1: Cohorts Used for the Mpox Serological Assay Development**

Cohort	Number	Naïve (#)	VAC (#)	Age (yrs)	M	F	UNK	Day
<b>Mpox-Confirmed (Total)</b>	<b>40</b>	<b>27</b>	<b>13</b>	<b>37</b>	<b>26</b>	<b>13</b>	<b>1</b>	<b>9 - 180</b>
2003	18	10	8	33	6	12	0	180
2022	22	17	5	40	20	1	1	9 -107
<b>Mpox-Negative (Total)</b>	<b>341</b>	<b>221</b>	<b>121</b>	<b>40</b>	<b>170</b>	<b>170</b>	<b>1</b>	<b>n/a</b>
Healthy	199	121	78	43	49	150	0	n/a
HIV	142	100	42	37	121	20	1	n/a
<b>Recent Vaccinees</b>	<b>15</b>	<b>13</b>	<b>2</b>	<b>38</b>	<b>14</b>	<b>1</b>	<b>0</b>	<b>25 - 88</b>
<b>Specificity Panel</b>	<b>115</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>115</b>	<b>n/a</b>

565

**Table 2: Diagnostic Performance of OPV Peptides and Antigens**

Antigen	ROC AUC	Cutoff (MFI)	Sensitivity % (95% CI)	Specificity % (95% CI)
<b>Mpox B21R-A</b>	0.85	795	93% (80 – 97)	67% (62 – 72)
<b>Mpox B21R-B</b>	0.85	602	85% (70 – 94)	75% (70 – 79)
<b>VAR B22R-A</b>	0.56	1466	66% (48 – 80)	52% (47 – 57)
<b>VAR B22R-B</b>	0.77	1828	81% (65 – 91)	72% (68 – 77)
<b>VAC A27L</b>	0.75	678	88% (72 -95)	61% (55 – 66)
<b>Mpox A29L</b>	0.77	960	84% (68 – 93)	59% (54 – 64)
<b>VAC A33R</b>	0.96	8469	91% (77 – 97)	91% (88 – 94)
<b>Mpox A35R</b>	0.97	7950	97% (85 – 100)	89% (85 – 92)
<b>VAC B5R</b>	0.90	3353	94% (81 – 99)	82% (78 – 86)
<b>VAC L1R</b>	0.81	711	65% (48 – 79)	84% (80 – 88)
<b>Mpox H3L</b>	0.96	6927	97% (85 – 100)	90% (86 – 93)

566

567

568

**Table 3: Sensitivity and Specificity of the NYS-OPV-MIA Based on Age Group**

<b>Mpox Negative Cohort</b>	<b>Sensitivity</b>	<b>Specificity</b>	<b>PPV*</b>	<b>95% CI‡</b>	<b>NPV†</b>	<b>95% CI‡</b>
Mpox-Negative Total	93%	98%	0.84	0.71 – 0.92	0.99	0.97 – 1.00
Presumed Naïve	93%	100%	1.00	0.90 – 1.00	0.99	0.96 – 1.00
Childhood Vaccination	93%	94%	0.84	0.71 – 0.92	0.97	0.93 – 0.99
Childhood Vaccination & Recent Vaccinees	93%	93%	0.80	0.67 – 0.89	0.98	0.93 – 0.99
Mpox-Negatives & Specificity Panel	93%	98%	0.77	0.63 – 0.87	0.99	0.98 – 1.00

\* Positive Predictive Value  
 † Negative Predictive Value  
 ‡ Confidence Interval


569

570


**Supplemental Table 1: Specificity Panel for Cross-Reactivity Testing of the NYS-OPV-MIA**

<b>Antibody Positive Sera</b>	<b>Number Tested</b>	<b>Positive (R)</b>	<b>Negative (NR)</b>
Anti-nuclear antibody (ANA)	5	0	5
<i>Anaplasma phagocytophilum</i>	3	1	2
<i>Bartonella spp.</i>	1	0	1
<i>Borrelia burgdorferi</i>	7	0	7
<i>Brucella spp.</i>	3	0	3
California Serogroup Viruses	4	0	4
Cytomegalovirus	5	1	4
<i>Coxiella burnetii</i>	3	0	3
Dengue Virus	3	0	3
Epstein-Barr Virus (EBV)	3	0	0
<i>Ehrlichia chaffeensis</i>	3	0	3
Enterovirus	2	0	2
Hepatitis B Virus	1	1	0
Hepatitis C Virus	2	0	2
HIV1	2	0	2
Herpes Simples Virus	13	0	13
Measles	5	0	5
Mumps	3	0	3
Varicella-Zoster	18	0	18
Parvovirus	3	0	3
Powassan Virus	3	0	3
Rheumatoid factor (RF)	2	0	2
<i>Rickettsia spp.</i>	2	0	2
Rubella	2	0	2
Syphilis	8	0	8
Western/Eastern Equine Encephalitis virus	1	0	1
West Nile Virus	6	1	5
Yellow Fever Virus	1	0	1
Zika Virus	2	0	2


A.



B.




C.




**Figure 1: Evaluation of Non-Vaccinia Peptides for the Detection of Mpox Infection**

Serum or plasma specimens from 341 presumed mpox-negative donors and 40 mpox confirmed patients were analyzed for antibody reactivity to peptide antigens derived from mpox and variola virus (VAR) by a microsphere immunoassay. **(A)** Median fluorescence intensity (MFI) of IgG reactivity to individual 31-mer peptides was used to generate ROC curves representing for mpox-derived B21R-A and -B (magenta) or VAR-derived B22R-A and -B (blue). **(B)** The log<sub>10</sub> MFI of IgG reactivity to mpox B21R-A and -B was plotted for mpox-negative, -positive, and vaccine control donors. The mpox-negative cohort was divided by birth year post- (presumed naïve) and pre-1972 (Childhood VAC) to estimate smallpox childhood vaccination status. **(C)** Log<sub>10</sub> MFI of IgG reactivity to mpox B21R-A and -B was plotted for mpox-negative donors post-1972 (>50) divided by “healthy” and “HIV”. Each dot represents an individual donor. Statistical significance was determined by the non-parametric Kruskal-Wallis test where \*p < 0.05 \*\*p < 0.001 \*\*\*p < 0.0001, and \*\*\*\*p < 0.00001 adjusted for multiple comparisons by Dunn’s test.

A.



B.



## Figure 2: Evaluation of Orthopoxvirus Antigens for the Detection of Mpox Infection


Serum or plasma specimens from 341 presumed mpox-negative donors and 40 mpox confirmed patients were analyzed for antibody reactivity to recombinant protein antigens derived from mpox or vaccinia virus (VAC) by microsphere immunoassay. **(A)** Median fluorescence intensity (MFI) of IgG reactivity to recombinant antigens from mpox or VAC (mpox A35R, solid magenta; VAC A33R, dashed magenta; mpox H3L solid light blue; VAC B5R dashed green; VAC L1R dashed orange; mpox A29L solid dark blue, VAC A27L dashed dark blue) were used to generate ROC curves used to represent the sensitivity (%) and specificity (%) of each antigen to detect mpox infection. **(B)** Log<sub>10</sub> MFI of IgG reactivity to OPV antigens (A33/35, B5R, L1R, and H3L) plotted for mpox-negative, -positive, and recent vaccinee donors. Each dot represents an individual donor. Statistical significance was determined by the non-parametric Kruskal-Wallis test where \* $p < 0.05$  \*\* $p < 0.001$  \*\*\* $p < 0.0001$ , and \*\*\*\* $p < 0.00001$  adjusted for multiple comparisons by Dunn's test.






**Figure 3: Distribution of OPV Antigen and Mpox Peptide Reactivity Among Negative and Mpox Cohorts**  
Heat maps indicate the relative index value (MFI/cutoff value) of each antigen (Mpox A35R, VV B5R, VV L1R, Mpox H3L, Mpox B21R-A, and Mpox B21R-B; vertical columns) for each serum/plasma donor (horizontal rows). Yellow corresponds to a negative index value ( $< 1.0$ ) below the clinical cutoff. The degree of red saturation corresponds to higher index values ( $> 1.0$ ) above the clinical cutoff.


A.




B.



C.




D.



#### **Figure 4: OPV Antigen Count and Algorithm for the New York State Orthopoxvirus (non-vaccinia)**

##### Microsphere Immunoassay for IgG Antibody Detection

**(A)** The number of OPV antigens (A33/35, B5R, L1R, and H3L) counted as reactive (R). Reactivity was defined as an MFI value at or above the calculated clinical cutoff value. The antigen count distribution was displayed as a violin plot for mpox-confirmed and mpox-negative cohorts. The mpox-negative cohort divided by birth year post- (presumed naïve) and pre-1972 (Childhood VAC) to estimate small-pox childhood vaccination status. **(B)** Serum or plasma specimens tested for mpox infection using a multiplexed microsphere immunoassay will be subjected to a 2-tier algorithm using a combination of mpox-specific peptides and OPV antigens. First, specimens will be considered for IgG reactivity to a set of cross-reactive OPV antigens (VAC A33R, mpox A35R, VAC B5R, VAC L1R, and mpox H3L). Samples with reactivity to 2 or fewer antigens will be considered non-reactive (NR; MFI < clinical cutoff) overall for mpox exposure while samples that test reactive (R; MFI > clinical cutoff) to 3 or more OPV antigens will move to the second tier of the algorithm. Next, samples will be considered for their reactivity to mpox peptides B21R-A and -B. Samples with no peptide reactivity will be considered NR for mpox infection. Samples with reactivity to one or more mpox peptides will be considered R for mpox infection. **(C)** Serum specimens from mpox-confirmed donors (n=40) and recent vaccinees (n=15) were analyzed for IgG reactivity to viral homologues VAC A33R and mpox A35R. Mpox confirmed donors were separated by birth year to simulate vaccination status before infection. Green circles indicate recent vaccinees. Grey circles indicate a birth year prior to 1972 (childhood vaccine), and blue circles indicate a birth year after 1972 (unvaccinated). Red circles in both groups indicate individuals infected in the 2003 mpox outbreak. The dashed line in each plot indicates the reactivity cutoff for the indicated antigen as determined by ROC curve. **(D)** Serum IgG reactivity ratio representing the mpox A35R MFI divided by the VAC A33R MFI. Green circles indicate recent vaccinees. Grey circles indicate a birth year prior to 1972 (childhood vaccine), and blue circles indicate a birth year after 1972 (unvaccinated). Red circles in both groups indicate individuals infected in the 2003 mpox outbreak. Statistical significance was determined by the non-parametric Kruskal-Wallis test where \*p < 0.05 \*\*p < 0.001 \*\*\*p < 0.0001, and \*\*\*\*p < 0.00001 adjusted for multiple comparisons by Dunn's test.



**Supplemental Figure 1: Distribution of Days Post-Onset for Mpox-Confirmed Cohort**

Histogram represents the number of specimens/donors at each day post-onset for the mpox-confirmed cohort. The 18 specimens at 180 days post-onset are from the 2003 group and the remainder of specimens are from the 2022 outbreak.